IMNN Latest Press Releases

-- March 31, 2026 --

IMUNON Reports 2025 Financial Results and Provides Business Update Highlighting Significant Progress with Pivotal Phase 3 Study Globe Newswire 8:00 AM

-- March 25, 2026 --

IMUNON Reports Updated Phase 2 Data Showing Continued Improvement in Median Overall Survival with IMNN-001 in Women with Newly Diagnosed Advanced Ovarian Cancer Globe Newswire 8:05 AM

-- March 24, 2026 --

IMUNON to Hold 2025 Financial Results and Business Update Conference Call on Tuesday, March 31, 2026 Globe Newswire 8:00 AM

-- February 5, 2026 --

IMUNON SHARPENS FOCUS ON ITS PROMISING PIVOTAL PHASE 3 OVARIAN CANCER STUDY Globe Newswire 8:05 AM

-- December 30, 2025 --

IMUNON Announces Pricing of $7.0 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules Globe Newswire 8:30 AM

-- December 29, 2025 --

IMUNON 2025, A TRANSFORMATIVE YEAR OF SIGNIFICANT CLINICAL ADVANCES, LOOKING AHEAD TO 2026 Globe Newswire 11:10 AM

Market Data Delayed 15 Minutes

Questions? Feedback?Olark live chat software